COMPARING THE POTENTIAL BUDGET IMPACT OF NOVEL THERAPIES FOR ADVANCED MELANOMA IN SECOND-LINE UNDER BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

被引：0

作者：

Tsuchiya, C. T. ^{[1
]}

Buschinelli, C. T. ^{[1
]}

Tobaruella, F. S. ^{[1
]}

Maximo, M. F. M. ^{[1
]}

Guzzo, M. R. ^{[1
]}

Goncalves, T. M. ^{[1
]}

机构：

[1] Roche Brazil, Sao Paulo, Brazil

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.jval.2013.08.2021

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A683 / A683

页数：1

共 47 条

[31] COST-MINIMIZATION ANALYSIS OF FLUDARABINE ASSOCIATED TO ALEMTUZUMAB (FLUCAM) VERSUS THE ASSOCIATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE SECOND LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Teich, N.
Teich, V
Benitez, R.
Schiola, A.
VALUE IN HEALTH, 2009, 12 (03) : A46 - A46
[32] ESTIMATING THE BUDGET IMPACT OF INTRODUCING INDACATEROL IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) PERSPECTIVE
Suzuki, C.
Silva, N. L.
VALUE IN HEALTH, 2011, 14 (07) : A489 - A490
[33] ESTIMATING THE BUDGET IMPACT OF ADDING OMALIZUMAB TO STANDARD THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA FROM PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
Suzuki, C.
Santoni, N. B.
Silva, N. L.
VALUE IN HEALTH, 2013, 16 (03) : A232 - A233
[34] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF INTRA-ARTICULAR SODIUM HYALURONATE VERSUS TOTAL ARTHROPLASTY IN THE TREATMENT OF KNEE OSTEOARTHRITIS UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Fernandes, R. A.
Quintella, F. F.
Teich, V
Carvalho, J. C. N.
Molinari, M. B.
Krambek, M. C.
VALUE IN HEALTH, 2009, 12 (07) : A437 - A437
[35] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS OLANZAPINE, QUETIAPINE AND ZIPRAZIDONE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Nishikawa, A. M.
Clark, O. A. C.
Pititto, L.
VALUE IN HEALTH, 2014, 17 (03) : A217 - A217
[36] CHOOSING FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER BASED ON BIOMARKER RAS STATUS: A BUDGET IMPACT ANALYSIS FROM BRAZILIAN HEALTH INSURANCE SYSTEM PERSPECTIVE
Souza, P., V
Simoes, A. C.
Zanini, F. E.
VALUE IN HEALTH, 2016, 19 (07) : A718 - A718
[37] COSTS ASSOCIATED TO TREATMENT OF METASTATIC HER2 POSITIVE BREAST CANCER AFTER PROGRESSION TO TRASTUZUMAB UNDER THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
Clark, O. A. C.
Teich, V
VALUE IN HEALTH, 2012, 15 (04) : A216 - A216
[38] THE RELATIVE CLINICAL AND ECONOMIC VALUE OF IPILIMUMAB IN THE TREATMENT OF METASTATIC MELANOMA VERSUS OTHER ANTI -CANCER AGENTS FOR METASTATIC DISEASES FROM A BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Stefani, S.
Tanaka, S.
Araujo, R.
Chagas, K.
Bernardino, G.
Donato, B. M.
VALUE IN HEALTH, 2015, 18 (07) : A819 - A819
[39] FERRIC CARBOXYMALTOSE IN THE TREATMENT OF IRON DEFICIENCY IN PATIENTS WITH HEART FAILURE FROM THE PERSPECTIVE OF PRIVATE HEALTH CARE SYSTEM: COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT IN BRAZIL
Campagnaro, M.
Picoli, R. M.
Castelano, N.
Clemente, V
Serna, Ramirez de Arellano A.
VALUE IN HEALTH, 2023, 26 (12) : S111 - S111
[40] A BUDGET IMPACT ANALYSIS (BIA) OF TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) IN HIGH-RISK PATIENTS WITH SYNTOMATIC SEVERE VALVE STENOSIS (SSVS) UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) PERSPECTIVE
Paladini, L.
Nishikawa, A. M.
Bueno, C. C.
Queiroga, M.
Lemos, P.
Clark, O. A. C.
VALUE IN HEALTH, 2013, 16 (07) : A704 - A704

← 1 2 3 4 5 →